A Randomised, Double-blind, Placebo-controlled Trial of<i>Trichuris suis</i>ova in Active Crohn’s disease
Jürgen Schölmerich(University of Hohenheim), Frank Seibold(Lindenhofspital), Harald Matthes(Forschungsinstitut Havelhöhe), Andreas Munk Petersen(University of Copenhagen), Klaus Fellermann(Apple (Israel)), Stefanie Howaldt, Jost Langhorst(ThyssenKrupp (Germany)), Gerhard Rogler(University Hospital of Zurich), Gottfried Novacek(Medical University of Vienna), Norbert Hesselbarth(Klinikum Ingolstadt), Niels Teich(Leipzig University), Oliver Bachmann(Medizinische Hochschule Hannover), Jan Wehkamp(Robert Bosch Hospital), Roland Greinwald(Dr Falk Pharma (Germany)), Claudia Ott(University Hospital Regensburg), Karin Dilger(Dr Falk Pharma (Germany)), Ralph Müeller(Dr Falk Pharma (Germany)), Jochen Klaus(University Hospital Ulm)
Cited by 65
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969